Voices
Marija Balic: Real-World Study on ctDNA-Based Testing in Metastatic HR+ Breast Cancer in Austria
Marija Balic/LinkedIn

Marija Balic: Real-World Study on ctDNA-Based Testing in Metastatic HR+ Breast Cancer in Austria

Marija Balic, Co-director of Magee Womens Cancer Program at University of Pittsburgh School of Medicine, shared a post on LinkedIn:

“We are pleased to share our latest addition, advancing both risk stratification and the clinical implementation of ctDNA-based testing for women with metastatic hormone receptor–positive breast cancer.”

Title: Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria

Authors: N. Dobrić, S.O. Hasenleithner, C. Suppan, E.V. Klocker, D. Hlauschek, R. Graf, C. Beichler, C. Albertini, D. Egle, D. Liu, A.M. Starzer, R. Bartsch, T. Moser, G. Rinnerthaler, P.J. Jost, E. Heitzer, N. Dandachi, M. Balic

Read the Full Article.

Marija Balic: Real-World Study on ctDNA-Based Testing in Metastatic HR+ Breast Cancer in Austria

Other articles about breast cancer on OncoDaily.

A.M. Starzer Breast Cancer C. Albertini C. Beichler C. Suppan cancer D. Egle D. Hlauschek D. Liu E. Heitzer E.V. Klocker G. Rinnerthaler M Balic Marija Balic N. Dandachi N. Dobrić OncoDaily Oncology P.J. Jost R. Bartsch R. Graf S.O. Hasenleithner T. Moser